Literature DB >> 33828245

A perspective on adverse health outcomes after breast cancer treatment in women with spinal cord injury.

Celine M Edwards1, Annemarie T Walters-Shumka1, Bonita Sawatzky2,3, Shira Standfield4, Tamara Shenkier1,5, Susan R Harris6.   

Abstract

Aging women face increased risks of both breast cancer and spinal cord injury (SCI). Unique treatment challenges for this population warrant consideration. Despite advances in breast cancer treatments, significant adverse health outcomes continue to occur. Cancer treatments can be detrimental to the quality of life of able-bodied women, but more so for women living with pre-existing SCI. The goal of this Perspective Paper is to inform rehabilitation professionals about the needs of women with SCI treated for breast cancer. Specific objectives were: (1) give an overview of breast cancer treatment-related adverse outcomes that need special attention in women with SCI; and (2) inspire researchers to study the consequences of breast cancer-related health conditions in women with SCI. We identified SCI-specific considerations for undergoing breast cancer surgery, chemotherapy, radiation and endocrine therapy. This paper attempts to raise awareness regarding these issues due to the lack of research attention they have received.

Entities:  

Year:  2021        PMID: 33828245     DOI: 10.1038/s41393-021-00628-2

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  2 in total

1.  The Severity of Bowel Dysfunction in Patients with Neurogenic Bladder.

Authors:  Anne P Cameron; Gianna M Rodriguez; Amy Gursky; Chang He; J Quentin Clemens; John T Stoffel
Journal:  J Urol       Date:  2015-05-06       Impact factor: 7.450

Review 2.  Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review.

Authors:  Janine T Hidding; Carien H G Beurskens; Philip J van der Wees; Hanneke W M van Laarhoven; Maria W G Nijhuis-van der Sanden
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.